Cellular BIOtechnology for prognosis and monitoring in renal TRANSplantation

Projektinformationen

TRANSBIO

ID Finanzhilfevereinbarung: 733248

DOI 10.3030/733248

Projekt abgeschlossen

EK-Unterschriftsdatum 26 September 2016

Startdatum 1 Januar 2017

Enddatum 30 Juni 2019

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 3 846 640,86

EU-Beitrag € 3 845 140,00

Koordiniert durch

BIOHOPE SCIENTIFIC SOLUTIONS FOR HUMAN HEALTH SL
Spain

Ziel

Kidney transplantation is the treatment of choice for patients with end-stage kidney disease (ESKD). However, although surgical techniques and postoperative care have greatly advanced, renal transplantation is not empty of challenges.
The most important challenge is to achieve the long-term survival of the transplanted organ. Graft survival depends on the ability of the recipe of not rejecting the “foreign organ”. Rejection is a naturally occurring process triggered by a biological response of the immune system, which main function in the body is to defend it against infectious organisms and other invaders. As such, the immune system is prepared to reject a “foreign organ”, something that is nowadays prevented by prescribing immunosuppressive therapies to the patients for their whole life. However, the use of immunosuppressive therapies entails important problems. On one side, suppressing the immune system implies severe side effects like opportunistic infections, cancer and other severe malignancies. On the other side, even under immunosuppressive therapies, about 50% of transplanted kidneys are lost during the first 10 years and this is because of an immune response usually described as chronic rejection. Therefore, the major challenges in ESKD deal with avoiding the side effects associated with immunosuppressant drugs and avoiding chronic rejection.
In the TRANSBIO project we aim at bringing to the healthcare market a technology for efficient clinical management of patients undergoing a kidney transplant based on a simple and non-invasive blood test.
Considering that worldwide, the number of people receiving renal transplantation annually is estimated at about 80,000 people, growing by approximately 6% annually and representing a prevalence of about 700 patients per million population, or what is the same about 5 million people living with a transplanted kidney, the TRANSBIO business opportunity seems unquestionable.

Wissenschaftliches Gebiet

• medical and health sciences › health sciences › public health
• medical and health sciences › basic medicine › immunology
• medical and health sciences › health sciences › personalized medicine
• medical and health sciences › clinical medicine › transplantation
• medical and health sciences › clinical medicine › nephrology › kidney diseases

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2016-2017

Finanzierungsplan

SME-2 - SME instrument phase 2

Koordinator

BIOHOPE SCIENTIFIC SOLUTIONS FOR HUMAN HEALTH SL

• Netto-EU-Beitrag: € 3 845 140,00
• Adresse: CALLE SANTIAGO GRISOLIA 2 PARQUE TECNOLOGICO DE MADRID ; 28760 TRES CANTOS MADRID ; Spanien
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Comunidad de Madrid › Comunidad de Madrid › Madrid
• Region: Comunidad de Madrid › Comunidad de Madrid › Madrid
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 3 846 640,86